反应详情

The title compound was prepared analogously to example A(236) substituting 2-{4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-propionitrile from example A(241) in place of 1-(4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5 -a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-cyclobutanecarbonitrile and 6-methyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde in place of 5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde. 1H NMR (400 MHz, CDCl3) δ: 1.66–2.00 (m, 8H), 2.30 (s, 2H), 2.36 (s, 2H), 2.49–2.62 (m, 4H), 2.69–2.85 (m, 3H), 3.49–3.59 (m, 1H), 3.89–3.94 (m, 1H), 4.01–4.08 (m, 2H), 4.18 (s, 1H).